The UC Berkeley-founded gene therapy developer plans to use the IPO proceeds to advance treatments for Fabry disease, cystic fibrosis and ophthalmological diseases.
4D Molecular Therapeutics, a US-based gene therapy spinout of University of California (UC) Berkeley, filed to raise $100m in an initial public offering on Monday that will enable university venture fund Berkeley Catalyst Fund to exit.
4D is developing gene therapies and will put part of the IPO proceeds toward a phase 1/2 clinical trial for 4D-310, a drug candidate for Fabry disease, a genetic disease that causes biomolecules known as sphingolipids to accumulate in organs leading to…
